Presentation is loading. Please wait.

Presentation is loading. Please wait.

Biomarker-based asthma phenotypes of corticosteroid response

Published byManoel Juan Mirandela Modified over 5 years ago

Similar presentations

Presentation on theme: "Biomarker-based asthma phenotypes of corticosteroid response"— Presentation transcript:

1 Biomarker-based asthma phenotypes of corticosteroid response
Douglas C. Cowan, BMedSci, MBChB, MRCP, PhD, D. Robin Taylor, MD, DSc, FRCP (Ed), Laura E. Peterson, BA, Jan O. Cowan, Rochelle Palmay, Avis Williamson, Jef Hammel, MS, Serpil C. Erzurum, MD, Stanley L. Hazen, MD, PhD, Suzy A.A. Comhair, PhD  Journal of Allergy and Clinical Immunology  Volume 135, Issue 4, Pages e1 (April 2015) DOI: /j.jaci Copyright © 2014 The Authors Terms and Conditions

2 Fig 1 Changes in biomarker values in asthmatic patients treated with ICSs. The percentage of asthmatic patients with decreases in biomarker values with ICS treatment for 28 days is shown proportionately by the size of the colored circles (blue, Feno values; green, sputum eosinophil counts [EOS]; and red, urinary BrTyr levels), and the percentage of asthmatic patients who do not have decreases in values of either of the 2 biomarkers in each panel is shown by black circles. Journal of Allergy and Clinical Immunology  , e1DOI: ( /j.jaci ) Copyright © 2014 The Authors Terms and Conditions

3 Fig 2 Receiver operating characteristic analysis describes the ability of each biomarker (ie, Feno values, sputum eosinophil counts, and urinary BrTyr levels) to classify asthmatic patients who respond to ICS therapy, as measured by 2 of 3 clinical outcomes (≥12% increase in FEV1 and/or ≥0.5-point decrease in ACQ score and/or ≥2 doubling dose increase in PC20AMP value). Journal of Allergy and Clinical Immunology  , e1DOI: ( /j.jaci ) Copyright © 2014 The Authors Terms and Conditions

4 Fig 3 ORs and 95% CIs for the association between a high biomarker value (Feno value, ≥35 ppm; sputum eosinophil count, ≥3%; and urinary BrTyr level, ≥0.45 ng/mg of creatinine) or biomarker combination (Feno and urinary BrTyr) and 2 positive clinical outcomes in response to ICS therapy. Results shown represent the ORs (solid circles) and 95% CIs (lines) of having a steroid response versus having no steroid response. Asterisks indicate a P value of less than .05, as determined by using the likelihood ratio χ2 test. Journal of Allergy and Clinical Immunology  , e1DOI: ( /j.jaci ) Copyright © 2014 The Authors Terms and Conditions

Download ppt "Biomarker-based asthma phenotypes of corticosteroid response"

Similar presentations

Buffering airway acid decreases exhaled nitric oxide in asthma Benjamin Gaston, MD, Robin Kelly, RN, Peter Urban, RN, Lei Liu, PhD, Edward M. Henderson,

Buffering airway acid decreases exhaled nitric oxide in asthma Benjamin Gaston, MD, Robin Kelly, RN, Peter Urban, RN, Lei Liu, PhD, Edward M. Henderson,
Jonathan A. Bernstein, MD, David M. Lang, MD, David A. Khan, MD 

Jonathan A. Bernstein, MD, David M. Lang, MD, David A. Khan, MD 
Simultaneously increased fraction of exhaled nitric oxide levels and blood eosinophil counts relate to increased asthma morbidity  Andrei Malinovschi,

Simultaneously increased fraction of exhaled nitric oxide levels and blood eosinophil counts relate to increased asthma morbidity  Andrei Malinovschi,
A randomized, double-blind, placebo-controlled pilot study of sublingual versus oral immunotherapy for the treatment of peanut allergy  Satya D. Narisety,

A randomized, double-blind, placebo-controlled pilot study of sublingual versus oral immunotherapy for the treatment of peanut allergy  Satya D. Narisety,
Risk of an asthma exacerbation after bariatric surgery in adults

Risk of an asthma exacerbation after bariatric surgery in adults
Analyses of asthma severity phenotypes and inflammatory proteins in subjects stratified by sputum granulocytes  Annette T. Hastie, PhD, Wendy C. Moore,

Analyses of asthma severity phenotypes and inflammatory proteins in subjects stratified by sputum granulocytes  Annette T. Hastie, PhD, Wendy C. Moore,
Ventilation defect percent in helium-3 magnetic resonance imaging as a biomarker of severe outcomes in asthma  David G. Mummy, MS, Stanley J. Kruger,

Ventilation defect percent in helium-3 magnetic resonance imaging as a biomarker of severe outcomes in asthma  David G. Mummy, MS, Stanley J. Kruger,
Alalia Berry, MD, William W. Busse, MD 

Alalia Berry, MD, William W. Busse, MD 
Comparative efficacy and anti-inflammatory profile of once-daily therapy with leukotriene antagonist or low-dose inhaled corticosteroid in patients with.

Comparative efficacy and anti-inflammatory profile of once-daily therapy with leukotriene antagonist or low-dose inhaled corticosteroid in patients with.
Effect of IVL745, a VLA-4 antagonist, on allergen-induced bronchoconstriction in patients with asthma  Virginia Norris, MRCP, Lee Choong, BSc, Duyen Tran,

Effect of IVL745, a VLA-4 antagonist, on allergen-induced bronchoconstriction in patients with asthma  Virginia Norris, MRCP, Lee Choong, BSc, Duyen Tran,
Asthma diagnosis and treatment: Filling in the information gaps

Asthma diagnosis and treatment: Filling in the information gaps
Santa Jeremy Ono, BA, PhD, Mark B. Abelson, MD 

Santa Jeremy Ono, BA, PhD, Mark B. Abelson, MD 
Sputum indoleamine-2, 3-dioxygenase activity is increased in asthmatic airways by using inhaled corticosteroids  Kittipong Maneechotesuwan, MD, PhD, Sirinya.

Sputum indoleamine-2, 3-dioxygenase activity is increased in asthmatic airways by using inhaled corticosteroids  Kittipong Maneechotesuwan, MD, PhD, Sirinya.
Stephen J. Fowler, MD, Gaël Tavernier, PhD, Robert Niven, MD 

Stephen J. Fowler, MD, Gaël Tavernier, PhD, Robert Niven, MD 
Obesity impairs apoptotic cell clearance in asthma

Obesity impairs apoptotic cell clearance in asthma
Decreased response to inhaled steroids in overweight and obese asthmatic children  Erick Forno, MD, MPH, Rachel Lescher, MD, Robert Strunk, MD, Scott Weiss,

Decreased response to inhaled steroids in overweight and obese asthmatic children  Erick Forno, MD, MPH, Rachel Lescher, MD, Robert Strunk, MD, Scott Weiss,
Dorothy M. Ryan, MD, Stephen J. Fowler, MD, Robert M. Niven, MD 

Dorothy M. Ryan, MD, Stephen J. Fowler, MD, Robert M. Niven, MD 
Jonathan A. Bernstein, MD, David M. Lang, MD, David A. Khan, MD 

Jonathan A. Bernstein, MD, David M. Lang, MD, David A. Khan, MD 
Roflumilast combined with montelukast versus montelukast alone as add-on treatment in patients with moderate-to-severe asthma  Eric D. Bateman, MD, Udo-Michael.

Roflumilast combined with montelukast versus montelukast alone as add-on treatment in patients with moderate-to-severe asthma  Eric D. Bateman, MD, Udo-Michael.
Airway inflammation in patients with asthma with high-fixed or low-fixed plus as-needed budesonide/formoterol  Ian D. Pavord, DM, FRCP, Peter K. Jeffery,

Airway inflammation in patients with asthma with high-fixed or low-fixed plus as-needed budesonide/formoterol  Ian D. Pavord, DM, FRCP, Peter K. Jeffery,

Similar presentations

Ads by Google